Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Focusing on the Menopausal Transition to Improve Mid-Life Women's Health
NCT06975111Phase 3Recruiting
- Sponsor
- University of Colorado Denver
- Start
- Mar 2026
- Primary completion
- Oct 2029
- Modality
- Peptides, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of fezolinetant, metformin, semaglutide in menopause, hot flashes, cardiovascular disease (CVD), obesity, Overweight, sponsored by University of Colorado Denver. Started Mar 2026; status: recruiting.
02
Drugs
03
Conditions
menopausehot flashescardiovascular disease (CVD)obesityOverweight
Beyond the preview
Go deeper on NCT06975111.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06975111.